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Chapter VII 
Obesity and Contraception 
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Abstract 
All sexually active youth, whether obese or normal weight, should be offered counseling 
regarding contraception and appropriate contraceptive methods. However, obese youth 
who are sexually active may be less likely than their normal weight peers to use 
contraceptives correctly. Methods of contraception for obese adolescents are reviewed in 
this discussion. Combined oral contraceptives (COCs) and the contraceptive patch have 
higher failure rates in obese versus normal weight females , though failure rates are lower 
noted with barrier contraceptives. The risk for venous thrombosis is higher in obese 
on COCs. Progestin-only pills and the levonorgestrel intrauterine system appear to 
safe and effective methods in obese females. Depot-medroxyprogesterone acetate, 
ring, and implants are also considered. 
/?T Corres:por1de1ace: Professor Donald E Greydanus, MD, Pediatrics and Human Development, lVil'·'""''"" 
University College of Human Medicine, Pediatrics Program Director, Michigan State 
Center for Medical Studies, Kalamazoo, MI 49008-1284 United States. Tel : 
6474; E-mail : Greydanus@kcms.msu.edu 
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Introduction 
Sexually active adolescents whether chronically ill or not, should be offered contraception if 
they are not willing to accept abstine11ce [1-7( Adolescents who are obese are at risk for 
unwanted pregnancy with its well-known .risks and thus, should also be offered safe and 
effective contraceptives. However, oyerv,rrifht or obese females are less likely to use 
contraception than their normal weight peers, despite their higher risk for pregnancy-related 
complications [8]. This chapter reyie~s)./Contraception in obese youth. In general, 
contraception is much safer than risks pgse~ i1Jecause of obesity and pregnancy. Effective 
methods that the clinician shotlld sp.~.~i~rrwsl~.qe combined oral contraceptives, mini-pills, 
depo-medroxyprogesterone ··.·· .. aST~~S~~ . ~.~M-~'%:~.fWa~ · ... xing, implantable contraception, and 
levonorgestrel intrauterine device (St!(!tapl~ l ). J?arrier methods are not generally effective in 
youth. 
Combined Ol"ijl ~pn~raceptives { cocs) 
Females with obesity have some ~sgr~~~S~iTt~~a,~?'with COCs due to higher basal metabolic 
rates, higher hepatic metapolisl.llofp!lZYt~t!~; ap.g dlJ.lg sequestration that is higher in adipose 
tissue; however, effic;:tsyi~llighT~· t~~~ ~9!~gj"it111:>arrier methods [9-13]. There are over 145 
brands of combineq ora}pontf~cep}ilf:es (~(JC~)usecithroughout the world, which generally 
contain both syntheti? t)str()f.~l1)~~~ ~?'~~~S!i~~rg9S~tin. In the United States, birth control pill 
brands are various . col11binatigns \5~tr~~SP. · ~Wi progestin. The usual estrogen is ethinyl 
estradiol as the estl"()g~n, }ll()~g~ ~if:t!j"i /~~~p.gsi l.l~P mestranol. Various progestins are used 
including norgestrel, Jevgpg~97~ttTbi! T~~~~g~~gl• •. diacetate, norethindrone acetate, 
norethindrone, desogestrel, norgestill?-ate,y!lor;t~yn()drel, drospirenone, and gestodene (not 
available in the US). The. ~ill ~~s P7?.~ s~~00~·tg. pe .a safe and effective contraceptive for 
reproductive women - especi~lly .for thg~e g~the .~dolescent age group. Thus, motivate 
adolescent females who are obese ca11 ~till\:)T 7~S.Wml.gy~ to use the COC despite the reported 
higher failure rates, mainly because •of tilt! ovep:~U efficacy of COCs and the known adverse 
pregnancy outcomes. 
Cunent recommendations are to beginwitllamonophasic pill, which has 30-35 meg of 
estrogen and 0.15 to 1.5 mg of progestin; Af.Cai triphasic pill. Triphasic pills are also 
recommended due to their low dose of~.~t.fg97n ~nd progestin. Careful monitoring and 
selection of patients for birth control pill us.~ will reduce complications of the pill to a 
considerable extent. Contraindications to oral contraception are reviewed in table 2. Sexually 
active youth who are on combined oral contraceptives are advised to use condoms as well. 
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Table 1. Contraceptive methods 
i L:orrmu11ea Oral Contraceptives (COCs) 
£'1'1,nt•r<~t>Pn1rivP patch 
C:fVJJrii-JlllllS (Progestin-only pills; POPs) 
Depo-Provera® (Depo-medroxy-progesterone acetate 
Lunelle® (estradiol cypionate and medroxyprogesterone acetate) 
Norplant I (withdrawn from the US market in 2000) 
Implanon (one rod system with etonogestrel) 
Jadelle (Norplant II: two silastic rods with levonorgestrel) 
vaginal ring (NuvaRing) 
...... ¥•r•n Devices 
Progestasert® IUD (with progesterone) 
ParaGard® (Copper T380A IUD) 
Mirena® (IUD with levonorgestrel) 
barrier contraceptives 
Cervical cap (Prentif Cavity-rim®) 
Condoms (male) 
Contraceptive sponge (vaginal) 
Diaphragm 
Female condom (Reality®) 
Spermicides (vaginal) 
o Evra Patch 
patch provides contraceptive efficacy similar to COCs but may have an 
risk for cardiovascular complications due to delivery of increased hormonal levels 
to oral COCs [14]. As noted with the birth control pill, obesity (weight over 90 kg 
~->vuu,~:.]) leads to reduced contraceptive efficacy, but still levels better than noted with 
contraceptives [12,13,15,16]. Dennatitis can occur a,s well with patch technology. 
with a history of skin allergy or exfoliative dermatological disorders may not be 
candidates for the patch. There is also an increased incidence in breast symptoms, 
most are reported to be mild or moderate [14,17]. Causes of increased risk 
failure include having the patch on over seven days, patch detachment, and 
to start a new patch after seven days of being off the patch. 
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Contraindications to OCPs 
The World Health Organization has .published a list of medical eligibility guidelines to 
provide clinicians with guidelines for COC use in those with various chronic illnesses that 
place users at increased risk of complications (see table 2) [18,19]. Those in WHO Category 
1 have no restrictions to OCP use, whil~ thqse in Category 2 present with some increased 
risk, though the risks of pregnancy exceed .them. Category 3 conditions have risks that are 
further increased, such that the pill is not. used U[ll~ss risks for pregnancy are even higher and 
no altemative contraceptive is available. Con~itJons found in Category 4 present risks that are 
so high that OCPs are not prescribed. 
Cardiovascular Complications 
Research has indicated an increased risk of cardipvascg~ar complications in females on COCs 
[7,20,21]. Obese females on birth control pill~hav~~e incr~~sed risk for pulmonary emboli, 
thrombophlebitis, and vascular thromboses. • Spllle•i<~f~gi<::s •• I1Qte a greater incidence of 
myocardial infarction and subarachnoid ht!llorrg~~e a§. ;\VelL[21]. An absolute OCP 
contraindication is a past history of ve11~~s t~·~~m~s~s •• (~'G~ .. ~11e the .risk of VT is more 
significant for the adolescent or young ad'l.llttea[l ~l1?zi,.~ltgz81Jlll()§is. Significant obesity is a 
VT risk factor andthe risk is i11creased inom.$[;$ . ~og~ser§[l2.,13,22]. 
Cardiovascular.deaths •. f[gm y<::eogs. ~~g .at1Ff~~1F81Jl~li9~~ip!lsil1 non-smoking females 
aged 20-24 yearsis 2-6per million p~r;rear.'Ghereisia 3-6/ fold increased risk factor for VT 
development in co~ .• ·.us7r.~···••i~I14 .... tce?. > ·st~~) f?f ~ i ~~ ieiR9<::r··••owith .. desogestrel versus 
levonorgestrel [7,20]. Thy VT.Gisk ii1; the g?~.Tral g~pulatip~ is Q .. 8 per 10,000 women per 
year, 3-4 for those . on COSs, <li•pg 62l2.i fos D?l~~lt·~ ~hg. ~re pregnant or postpartum 
[20,23,24]. Most who develop .veno~sthro~gpsisgp nothave identified VT risk factors. 
Table 3 lists screening questions to use owe<::.l1 con§i~eripRgcPs for contraception. In general, 
if there is no overt positive family history for VI', one does not need to screen for factor V 
Leiden or other prothrombotic mutations. 
Table 2. WHO medical eligibility categ()ries f()r OCPs. Used with permission (3] 
Category one (no restrictions) 
Antibiotics 
Benign breast disease 
Benign ovarian tumors 
Cervical ectropion 
Dysmenorrhea, 
Endometriosis 
Epilepsy 
Family history of breast cancer 
Gestational trophoblastic disease (benign or malignant) 
Headaches (mild) 
History of ectopic pregnancy or abortion (postabortion after first or second trimester), 
History of gestational diabetes 
Increased STD risk 
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Iron deficiency anemia 
Irregular menstmal bleeding 
Obesity 
Ovarian or endometrial cancer 
Past pelvic surgery 
Pelvic inflammatory disease 
Postpartum at or over 21 days 
Thyroid disorders (as hypo/hyperthyroidism, simple goiter) 
Varicose veins 
Various infections :malaria, tuberculosis, others) 
Sexually transmitted diseases 
Viral hepatitis carrier 
two (caution) 
Cervical cancer 
Diabetes mellitus (uncomplicated) 
Headaches (severe and if they start after beginning OCPs) 
Hype1tension at 140-159/100-109 mm Hg 
Major surgery without prolonged immobilization 
Migraine headaches without focal neurologic involvement. 
Patients who have a hard time taking the OCP cmTectly: 
drug or alchohol abuse 
mental retardation 
persistent history as poor OCP takers 
severe psychiatric disorders 
Sickle cell disease or sickle C disease 
Undiagnosed breast mass 
three (Usually no OCP given) 
Gallbladder disease 
Lactating (6 weeks to 6 months), 
Less than 21 days postpa1tum 
Medications that interfere with OCP efficacy 
Undiagnosed abnormal vaginal/uterine bleeding. 
four (OCP contraindicated) 
Breast cancer 
Cerebrovascular accident (active or history) 
Complicated stmctural heart disease (with pulmonary hypertension, atrial fibrillation or history of 
subacute bacterial endocarditis) 
Coronary (or ischemic) heart disease (active or history) 
Deep vein thrombosis or pulmonary embolism (active of history) 
Diabetes mellitus (complicated with retinopathy, neuropathy, nephropathy) 
Headaches (including migraine headaches) with focal neurologic symptoms 
Hypertension (severe: ( 160+/11 0+ mm Hg or with vascular complications) 
Lactation under 6 weeks postpartum 
Liver disease (including liver cancer, benign hepatic adenoma, active viral hepatitis, severe 
cirrhosis) 
complicated 
the lower extremities and/or immobilization 
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Table 3. Screening questions about personal/family history of thromboembolism 
1. Is there a history of blood clots in legs or lungs in close family members, including 
uncles and aunts? 
2. Have any of your close family members been in the hospital for leg/lung blood clots? 
3. Have you and/or close family members evertaking blood thinners? 
4. What were the circumstances that led to blood clot (s), as for example while as a result of 
traveling by airplane? 
The pill should be stopped before situations arise requiring prolonged bed rest as with some 
surgeries. Hypertension and hyperlipidemia maybe complications of obesity. Blood pressure 
should be regularly checked since it may rise i!1§0me patients.25 If there is a family or 
personal history of hyperlidemia, OCPs m~.:r :·~tillih~ prescribed if low-density lipoprotein 
(LDL)levels remain < 160 mg/dl andtriglyceridf)s < 250. COCs are not recommended for 
adolescents (obese or not) if they have (;gp_gestiy~}ieart failure, cardiac shunts, or low output 
heart disorders.5,26 
Diabetes Mellitus 
Diabetes mellitus may be a . complic~~ioi} bf ~t· . oc .cl1r incidental of obesity. Current evidence 
suggests that combined oral contr~p~ptiye~ ~r~ safe for obese females with well-controlled 
diabetes mellitus typesl and2[12]. 88ys do ngtworsen the metabolic status in diabetic 
females [12,13,27]. (Sareisn~eded ~79~~se. ofsoncernover worsening metabolic status due 
to progestins and · .. increa~e~· i.risk<f~~· t1lr.()ZSl~g.t~n~~~~c events due to estrogen [28]. COCs 
should not be offered if ·they are Ae\ poor llletabolic control or have hypertension, 
nephropathy, or retinopathy. Other C()ntr~cTptive methods that are safe and effective in 
females with diabetes include progestin,_o!llypil1s .agd the intrauterine device (IUD) [13]. 
There may be an increase in recurrent, treatirient'",resistant vaginal yeast infections in diabetic 
youth with an IUD [28]. The use of degg~~7grpX)'Pr9gesterone acetate or levonorgestrel 
implant may worsen the metabolic status in.qiAPf!tic; fy]Jlales. 
Migraine Headaches 
Caution is advised when prescribing the birth control pill to an individual with a history of 
migraine headaches and the COC should be stopped if the migraine aura or headache pattern 
worsen on COCs [1-4]. If the individual has a history of severe migraines or migraines with 
prolonged auras (as with the hemiplegic or ophthalmoplegic types) the pill should not be 
given. If the migraine headache and/or the aura worsen while on the pill, it should be stopped 
immediately. Careful monitoring is advised when placing women with migraines on the pill. 
It is not known if obesity presents a greater risk for migraine-related cerebrovascular 
accidents that may be increased by the COCs or patch. 
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Conditions 
"""'"'" with active liver disease should not be placed on OCPs. The effect of obesity-related 
(nonalcoholic steatohepatitis) on COCs not clear at this time. Youth with obesity may 
risk for depression and no obesity-related complications with SSRis are repmied. 
antidepressants can reduce estrogen levels with increased BTB but not reduced 
'""'"'""'•" ·'~ efficacy. St. John's wart is used to treat depression and can lead to increased 
bleeding and anecdotal reports of reduced OC efficacy [ 1-4]. Some females 
obesity are at increased risk for fungal infections and some anti-fungal agents are potent 
enzyme inducers with resultant decreased contraceptive efficacy; these agents include 
vin, ketoconazole and itraconazole. Other drugs can interfere with contraceptive 
such as rifampin. Table 4 lists management principles for miscellaneous side effects 
estin-only Pills (POPs) (Mini-Pills) 
contain 0.35 mg ofnorethindrone (Micronor®; Nor-Q.D®) and0.075mg ofnorgestrel 
. Obesity may be associated with reduced contraceptive efficacy [13]. POPs are. 
used in those individuals having disorders where estrogen maybe contraindicated -
as sickle cell anemia, cyanotic hea1i disease, severe hypertension, diabetes mellitus, and 
(see table 2). Some clinicians have not recommended the mini-pill for teenagers 
of its increased pregnancy rate as well as frequent breakthrough bleeding and 
enc>rr11ea noted in some females on the mini-pill [1-4]. POPs are avoided in those with a 
of ectopic pregnancy and those taking certain medications (as anticonvulsants, 
vin and rifampin). There is no increase in VT in obese females on progestin-only 
12,13]. 
Table 4. Management of some oral contraceptive related problems 
monilial vaginitis 
Anti-acne measures and medications 
Anti-fungal agents (as fluconazole); persistent infections: 
Look for underlying factors, as diabetes mellitus, other 
endocrinopathies, use of antibiotics, infected male genital 
tract, others. Oral nystatin may reduce gastrointestinal 
reservoir; use anti-fungal agents for a protracted period of 
treatment. 
Usually a transient condition; ensure patient is taking the pill 
each day; higher estrogen pill or supplemental estrogen may 
help; evaluate for .underlying pathology 
COCs are not teratogenic but should be stopped as ~~..,··~ ~ ... ,. > •• ,.,, •.. 
the pregnancy is identified. 
Use a lower 11 
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Depot-Medroxyprogesterone Acetate (DMPA) 
The main injectable contraceptive ayail~ple (inthe US is depomedroxy-progesterone acetate 
(Depo-Provera®). It is given in a dose o£150 mg intramuscularly every three months and 
DMPA has a better contraceptiv~ ·Tffi~~.9~i thaJ1)he COC with a failure rate of 0.3%. No 
decreased contraceptive efficacy i s ggted igobese females versus normal weight females 
[ 13]. Its mechanism of actioninclmles an induction of a low FSH/LH level, low LH surge, 
production of an atrophic eq49l1J..#tzi~lc~?ii al,le>thiclcening of the cervical mucus. Side effects 
include irregular menses, amenq~·~Ta,',a:n&.• . 1J~east tenderness, weight gain (with bloating), 
decrease in bone density, 4&crea~& R~i~~.p4-d(msity ·lipoprotein levels, and some behavioral 
changes such as irritability anqgepre§~~Rn. 
It is useful where a hi~~ly>rrtf:&:!iYR :?gtr~ctptive is needed and where the side effects of 
an estrogen-type contraceptiv&frustp&iavoiged. Thus, it has been used for individuals with 
cyanotic heart disease, §if~t-c~.}} ~g5t1~.~' t~yp~nbophlebitis, and others. Internationally, 
psychotic and retarded i11divig~~ls w~q are ~j risk for pregnancy have been prescribed this 
injectable ·contraceetiye. I~ .. i~ Bqg~.~gt1·eg . 5q lJt .a . very effective hormonal contraceptive for 
obese females, despiteit~e }"e~qged:•.9~~ggtJigbodycomposition towards fatness and central 
redistributiono{fat follq'\ingitsuse.·W\''C .... \)F .. ' 
Another .inject<J:1Jle• ~811~apept~'\fe•Y J::.,~ellt~ (5 mg estradiol cypionate and 25 mg 
medroxyprogesterone a~etate I.NfP~tC]),'\as approved by the FDA in 2000. Estrogen is 
added to allow abettermenstru(ltperipgi ~~)'t~;than seen with Depo-Provera. Less weight 
gain is noted and overall adverse •Fe{fects life similar to COCs [29]. Lunelle® is given 
intramuscularly every 28-30 daysaggifh~~i~:~ip~contraceptive efficacy rate [30]. One study 
noted that there was a weight gain o£0,9 k~lto 1.8 kg if the female weighed under 68 kg 
versus a weight gain of 1.4 to 3.6 J,cg if'pver 68 kilograms [30]. There is no overt 
contraindication in females with obesity;. 
Emergency Contraceptives 
Emergency contraceptives (EC) are . ~ni611& !he ··)11()St controversial and under prescribed 
contraceptive methods (seee table 5)[31} .• ~1Je~i~is >not a contraindication to use of ECs. 
Anti-emetics can be given to preventthe tr7quentoccurrence of nausea and emesis that 
occurs with high dose estrogen; th~s,ap ~1ltiefrT~i9.s~quld be taken an hour before taking 
these pills. In 1999, the US Food a11qi?rug~9mini§tration (FDA) approved of Plan B®, a 
progestin-only method with two tables of O.'Zt; mg pflevonorgestrel. The first tablet is taken 
immediately and the second tablet is takent'N()hol1rs later. Because Plan B® contains no 
estrogen, nausea and vomiting is uncomn1:on.and there is no need to obtain a pregnancy test 
before adrninistation. Thus, Plan B may be better tolerated than those with estrogen [32]. 
Though the official recommendation is thatthey must be used within three days of coitus, 
they may be effective in pregnancy prevention within five days. 
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Table 5. Emergency contraceptives 
Ovral® : 2 tablets followed by 2 tables in 12 hours 
Lo/Ovral®, Nordette® or Levien®: 4 tabs and 4 more in 12 hours 
Plan B®: levonorgestrel, 0.75mg followed by 0.75 mg in 12 hours 
Preven® Emergency Contraceptive Kit 
Ovrette®: 20 tabs and 20 more in 12 hours 
TriPhasil® or Tri-Levlen® : 4 tabs, and 4 more in 12 hours 
ng® (Vaginal Ring) 
81 
is a soft, flexible, transparent vaginal ring made of a ethylene vinyl acetate copolymer; it 
outer diameter of 54 mm and a cross-section of 4 mm [2,4] . There are two steroid 
cores that provide a daily bmmonal release of 15 meg of ethinyl estradiol and 120 
of etonogestrel (an active metabolite of desogestrel) [30,33]. Side effects include 
withdrawal bleeding, vaginal discomfort, nausea, headache, nervousness, acne, 
tenderness, leukon hea, reduced libido, and slight weight gain. Thereis an increased 
of thrombotic diseases [34]. There is usually less inegular bleeding than seen with 
. Extremely overt weight females may have trouble inserting the ring. Obesity itself 
not effect the contraceptive efficacy of the NuvaRing and it is considered as one of the 
effective hormonal contraceptive methods for obese females. 
was the first implantable contraceptive developed and was very effective as a 
It contains six silastic levonorgestrel-containing rods; however, it was 
from the United States market in 2000 [2,4]. The Jadelle® implant (Norplant II) 
two silastic rods with levonorgestrel and Implanon® contains one rod (vinyl 
acetate polymer) with etonogestrel [7,35]. Both Jadelle® and Implanon® are 
by the FDA for three years and are not contraindicated in obesity, though both may 
some weight gain .. Though obese females have been found to have lower serum 
levels, there is no reduced efficacy noted with Implanon in obese female [13,36]. 
rine Device (IUD) 
three IUDs which currently are used in the United States: Progestasert IUD®, the 
(Copper T380A) and the Mirena IUD [2,4,37-39]. Previous controversial IUD 
pelvic inflammatory disease (PID) have limited its application to aqolpscents. 
the IUD is an excellent contraceptive method with no contraindicatio1l .• il1/ ?bese 
The Mirena® IUD (Levonorgestrel-containing IUD; LNG-IUD) was FDA-aPPfc?s®~ 
for five years and contraindications are active PID, prosthetic heartvalves, histql)'()f 
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subacute bacterial· endocarditis, and distorted uterine cavity. The most common side effect is 
menstrual bleeding; there is increased bleeding and spotting during the first 3-6 months after 
insertion that usually decreases after this time. Obese females have an increased incidence of 
dysfunctional uterine bleeding and ~ndometrial hyperplasia, making the Mirena IUD a good 
contraceptive choice for obese fem1:1,)es .ueeding contraception [12]. No reduced contraceptive 
efficacy has been noted because of pbe~ity [13 ,40]. In diabetic patients, an increase in vaginal 
yeast infections should be taken underconsideration. 
Conclusions 
Contraceptive efficacy is reduc~di~• ()~~~~fet~al~s oil the combined oral contraceptive and 
the contraceptive patch; ho\V.~v;r, Jfe { ef~~~c~ is still above that noted with banier 
contraceptives. COCs are safewi~f ~Rs~.~ ffl1lales \Vith diabetes mellitus if they are in good 
control and do . nothave Tiepftfop~th~, x:~in~pa~hy, n~11ropathy, or hype11ension. Progestin-
only pills are safe in obfse :~111~lr~ Rl!t i~Scr:a~~d contraceptive efficacy is noted in all 
females on this c~Tit~~s~gtiv~ p:u::teg~· ~l:>ssi!)' i~ 11~t a contraindication to use of depo-
medroxyproge~teron~ ac~tatf:, ~UJ.:)• l:l.Tig jTI~f~X~~ip,~l .. l"il19· · The mini-pill and levonorgestrel 
IUD may be the safest for obesefemal~s l1~f:di11gp8ntraception [ 12]. 
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